直播间的疯狂种草，西子健康一路狂奔，正闯关港交所。 近日，湖南西子健康集团股份有限公司正式递交上市申请，中信证券担任独家保荐人，试图成为"抖音 直播+运动营养赛道第一股"。 从翻看其招股说明书，不难发现，西子健康狂奔的背后是，"超60%收入绑定抖音、近半营收砸进营 销、研发投入不足1%"的残酷现实。 这家被流量催熟的品牌，正在接受资本市场最严苛的考验。 逆袭，直播造神话 复盘西子健康的发家史，堪称是所有新消费品牌的流量速成范本。 2013年成立的西子健康，前七年一直是个"打工人"，主营第三方运动健康产品代理，赚着微薄的渠道差 价。 直到2020年前后，该公司踩中抖音直播电商的风口，果断转型做自有品牌，从此一飞冲天。 业绩也是一路狂飙：2023年营收14.47亿元，2024年增至16.92亿元，2025年前三季度达到16.09亿元，几 乎追平去年全年。 更亮眼的是，西子健康的自有品牌贡献营收占比从2023年的42.4%攀升至2025年前三季度的97.3%，彻 底摆脱了对代理业务的依赖。 转型自有品牌也让毛利率大幅跃升，从2023年的44.4%一路涨至2025年前9个月的59.5%，接近60%的毛 利率，在食品行 ...

近日，国内运动营养及功能性食品领域新锐企业西子健康正式向香港联合交易所递交上市申请资料，迈 出企业资本化进程的关键一步。依托多品牌矩阵布局、全链路智能制造体系与持续的研发创新投入，西 子健康在行业高速发展浪潮中实现营收与利润双增长，此次冲击港股，更是为企业迈向高质量发展新阶 段筑牢资本根基，也为国内运动营养行业的产业化升级注入新活力。 作为专业的运动营养品牌运营商，西子健康深耕行业发展趋势，打造了FoYes、fiboo、谷本日记、 HotRule四大核心新锐品牌，构建起丰富多元的产品矩阵。其产品覆盖蛋白粉、复合乳清蛋白粉、肌酸 等运动营养核心品类，同时布局功能性软糖、咖啡等潮流功能性食品，精准触达健身爱好者、都市轻养 生人群等不同消费群体的个性化健康需求，形成了差异化的市场竞争优势。亮眼的业绩数据印证了企业 的发展实力，2023年、2024年及2025年前三季度，西子健康分别实现营业收入14.47亿元、16.92亿元、 16.09亿元，同期净利润达9385.6万元、1.49亿元、1.18亿元，营收规模稳步扩大，盈利能力持续提升， 展现出强劲的经营韧性与发展潜力。 当下，我国营养及健康食品市场正迎来黄金发展期， ...

Core Insights - The Chinese nutrition and health industry is experiencing a surge in IPO activities, indicating a shift from local operations to global expansion and a focus on scientific validation [4][5]. IPO Developments - In 2025, several companies in the nutrition and health sector are set to go public, covering the entire supply chain from raw materials to manufacturing and branding [4]. - Dongpeng Beverage plans to list on the Hong Kong Stock Exchange in early 2026, aiming to raise over HKD 10.1 billion, marking the largest IPO in the non-alcoholic beverage sector in Hong Kong history [4]. - Xianle Health is advancing its H-share listing while optimizing its global CDMO platform by divesting non-core assets [4]. - Ruoyuchen has submitted its application to the Hong Kong Stock Exchange, focusing on its proprietary brand FineNutri to transition from a service provider to a brand owner [4]. - Other companies like Jiyuan Group and Hengmei Health are also pursuing listings to enhance their production capacities and market presence [4][5]. Regulatory Updates - The National Market Supervision Administration has released several guidelines and regulations affecting the health and nutrition sector, including the review of special medical formula food production licenses and the management of live-streaming e-commerce [6][7]. - New regulations have been introduced to ensure compliance in the marketing of health products, including a ban on certain food sales in live-streaming environments [6]. Market Trends - There is a notable increase in demand for health supplements, with sales of ginseng and other tonic products rising by 55% year-on-year during the New Year holiday [17]. - The import of medical and health products has also seen significant growth, with a 70.4% increase in imports in Hubei province in 2025 [17]. Industry Insights - The current wave of capital influx is not merely for financing but signals a critical transition in the industry towards scientific validation and global operations [4]. - Companies with genuine research capabilities, compliant product systems, and international perspectives are expected to gain a competitive edge in high-quality development [4].

Core Viewpoint - Xizi Health, a sports nutrition food brand heavily reliant on Douyin for its growth, has submitted its listing application to the Hong Kong Stock Exchange, with 99% of its revenue coming from online sales and less than 1% invested in R&D [2][9]. Group 1: Company Overview - Xizi Health primarily offers products such as protein powder, creatine, and functional gummies, with a brand portfolio that includes FoYes, fiboo, Gu Ben Ri Ji, and Hot Rule [2]. - The company has transitioned from a third-party brand operator to a brand owner, achieving significant sales milestones within months of launching its products [4][5]. Group 2: Financial Performance - Revenue from self-owned brands surged from 613 million RMB in 2023 to 1.497 billion RMB in 2024, marking a 144% year-on-year growth, and further increased to 1.566 billion RMB in the first three quarters of 2025, a 38.7% increase from the same period in 2024 [4][5]. - Gross profit margin improved from 44.4% in 2023 to 59.5% in the first three quarters of 2025, with gross profits rising from 642 million RMB in 2023 to 957 million RMB in 2025 [5]. Group 3: Marketing and Sales Strategy - Marketing expenses have risen significantly, accounting for over 40% of total revenue, leading to a decline in net profit margin from 8.9% in 2024 to 7.4% in 2025 [6][8]. - Nearly 99% of Xizi Health's revenue is generated from online direct sales, with Douyin contributing over 60% of this revenue [10][12]. Group 4: Supply Chain and Risks - The company faces supplier concentration risk, relying on a few suppliers for a significant portion of its products, which could adversely affect its supply chain and operations [17].

Industry Overview - The health and nutrition food industry in China is experiencing significant growth, with retail sales increasing from RMB 297.9 billion in 2020 to an expected RMB 405.7 billion in 2024, representing a compound annual growth rate (CAGR) of 8.0%. By 2029, the market is projected to reach RMB 645.2 billion, with a CAGR of 9.7% [1]. Company Profile - Xizi Health, established in 2013, is a leading player in the sports nutrition food sector in China, focusing on the research, production, and sales of sports nutrition products. The company operates four major brands: FoYes, fiboo, Guben Diary, and HotRule, covering various product categories such as whey protein powder, creatine, functional gummies, and energy supplements [2][3]. Marketing Strategy - Xizi Health employs a data-driven marketing strategy, utilizing online traffic operations and customized strategies for different brands and sales channels. The company has built an efficient multi-channel sales network centered on direct-to-consumer (DTC) sales, which has allowed it to effectively reach consumers [3]. Financial Performance - The company's revenue has shown substantial growth, with figures of RMB 1.447 billion in 2023, RMB 1.692 billion in 2024 (up 16.9% year-on-year), and RMB 1.609 billion in the first nine months of 2025 (up 23.0% year-on-year). The net profit also increased, reaching RMB 94 million in 2023, RMB 149 million in 2024, and RMB 118 million in the first nine months of 2025, with growth rates of 58.5% and 1.9% respectively [4]. Cost Structure - Despite high revenue growth, Xizi Health faces challenges related to rising marketing expenses, which increased from RMB 473 million in 2023 to RMB 756 million in the first nine months of 2025. The sales expense ratio rose from 32.7% in 2023 to 47% in the first nine months of 2025, impacting profit margins [5]. Cash Flow and Operational Efficiency - The company's operating cash flow has declined from RMB 270 million in 2023 to RMB 66 million in the first nine months of 2025, indicating that high growth has come at the cost of significant working capital usage [6]. Strategic Transition - Xizi Health has successfully transitioned from third-party brand operations to a self-owned brand model, with self-owned brand revenue increasing from RMB 614 million in 2023 to RMB 1.498 billion in 2024, a growth of 144.0%. By the first nine months of 2025, this revenue further increased to RMB 1.567 billion, up 38.7% year-on-year [7]. Revenue Concentration - The company's revenue is highly concentrated in online channels, with online sales accounting for approximately 99.4% in 2023, 99.0% in 2024, and 98.9% in the first nine months of 2025. Notably, Douyin (TikTok) is a critical revenue source, contributing 45.5% to 62.8% of total sales during the same periods [8].

Industry Overview - The health and nutrition food industry in China is experiencing significant growth, with retail sales increasing from 297.9 billion RMB in 2020 to an expected 405.7 billion RMB in 2024, representing a compound annual growth rate (CAGR) of 8.0%. By 2029, the market is projected to reach 645.2 billion RMB, with a CAGR of 9.7% [1]. Company Profile - Xizi Health, established in 2013, is a leading player in the sports nutrition food sector in China, focusing on the research, production, and sales of sports nutrition products. The company operates four major brands: FoYes, fiboo, Guben Diary, and HotRule, covering various product categories such as whey protein powder, creatine, functional gummies, and energy supplements [2][3]. Marketing Strategy - Xizi Health employs a data-driven marketing strategy, utilizing online traffic operations and customized strategies for different brands and sales channels. The company has built an efficient multi-channel sales network centered on direct-to-consumer (DTC) sales, which has allowed it to effectively reach consumers [3]. Financial Performance - The company's revenue has shown substantial growth, with figures of 1.447 billion RMB in 2023, 1.692 billion RMB in 2024 (up 16.9% year-on-year), and 1.609 billion RMB in the first nine months of 2025 (up 23.0% year-on-year). Net profit also increased, reaching 94 million RMB in 2023, 149 million RMB in 2024 (up 58.5% year-on-year), and 118 million RMB in the first nine months of 2025 (up 1.9% year-on-year) [4]. Cost Structure - The company's sales expenses have risen significantly, from 473 million RMB in 2023 to 756 million RMB in the first nine months of 2025, leading to an increase in the sales expense ratio from 32.7% in 2023 to 47% in 2025. This has impacted profit growth, with net profit growth lagging behind revenue growth due to rising sales expenses [5]. Cash Flow and Operational Efficiency - Xizi Health's operating cash flow has declined from 270 million RMB in 2023 to 66 million RMB in the first nine months of 2025, indicating that high growth has come at the cost of significant working capital usage [6]. Strategic Transition - The company has successfully transitioned from third-party brand operations to a self-owned brand model, with self-owned brand revenue increasing from 614 million RMB in 2023 to 1.498 billion RMB in 2024 (up 144.0% year-on-year) and further to 1.567 billion RMB in the first nine months of 2025 (up 38.7% year-on-year). The gross margin has also improved, rising from 44.4% in 2023 to 59.5% in the first nine months of 2025 [7]. Revenue Concentration - Xizi Health's revenue is highly concentrated in online channels, with online sales accounting for approximately 99.4% in 2023, 99.0% in 2024, and 98.9% in the first nine months of 2025. The company heavily relies on Douyin, which contributed 45.5% to 62.8% of total revenue during the same periods. The DTC sales model accounted for about 88.4% in 2024 and 89.8% in the first nine months of 2025 [8].

Core Viewpoint - Xizi Health Group has submitted its listing application to the Hong Kong Stock Exchange, with a significant reliance on online sales channels, particularly through Douyin, raising concerns about its business model amid rising traffic costs [1][3]. Group 1: Financial Performance - Xizi Health's projected revenues for 2023, 2024, and the first nine months of 2025 are approximately 1.447 billion, 1.692 billion, and 1.609 billion yuan, respectively, with net profits of 94 million, 149 million, and 118 million yuan during the same periods [1]. - The company ranks third among Chinese sports nutrition food brand operators and is noted as one of the fastest-growing brands in the sector from 2022 to 2024 [2]. Group 2: Revenue Sources - Approximately 99% of Xizi Health's revenue comes from online channels, with Douyin accounting for over 60% of this income, indicating a heavy reliance on digital platforms for sales [3]. - The company's main brands include FoYes, fiboo, Gu Ben Diary, and HotRule, with FoYes and fiboo contributing 35% and 36.7% to revenue, respectively, in the first three quarters of 2025 [2]. Group 3: Marketing and R&D - Xizi Health's marketing expenses have increased significantly, with sales costs rising from approximately 473 million to 756 million yuan, representing an increase in the sales expense ratio from 32.7% to 47% [4]. - R&D expenditures are notably low, with only 0.5% to 0.7% of revenue allocated to R&D, raising concerns about the company's technological capabilities and potential for product differentiation [4][5]. Group 4: Production and Quality Control - The company primarily relies on third-party manufacturers for its products, which raises concerns about quality control and supply chain management [5]. - Complaints regarding product quality, including safety issues, have been reported by consumers, indicating potential risks associated with the company's reliance on external production [5].

Core Viewpoint - Xizi Health Group has submitted its listing application to the Hong Kong Stock Exchange, with a significant reliance on online sales channels, particularly through Douyin, raising concerns about its business model amid rising traffic costs [1][5]. Financial Performance - Xizi Health's projected revenues for 2023, 2024, and the first nine months of 2025 are approximately 1.447 billion, 1.692 billion, and 1.609 billion yuan respectively, with net profits of 94 million, 149 million, and 118 million yuan for the same periods [1]. - Sales expenses have increased significantly, reaching approximately 473 million, 751 million, and 756 million yuan for the respective years, with the sales expense ratio rising from 32.7% to 47% [6]. Revenue Sources - The company generates 99% of its revenue from online channels, with Douyin accounting for over 62.8% of its income, indicating a heavy dependence on a single platform [5][6]. - The main brands under Xizi Health include FoYes, fiboo, Guben Diary, and HotRule, with FoYes and fiboo contributing 35% and 36.7% to revenue respectively [4]. Market Position - Xizi Health ranks third among Chinese sports nutrition food brand operators and is noted as one of the fastest-growing brands in the sector from 2022 to 2024 [4]. - The company has achieved top rankings in GMV for its products on Douyin, indicating strong market presence [4]. Marketing and R&D - The company employs a "data-driven marketing" strategy, focusing on direct-to-consumer sales while maintaining a low R&D expenditure, which is less than 1% of revenue [6][7]. - Concerns have been raised regarding the low R&D investment, which may affect long-term growth potential and investor confidence [7][8]. Production and Quality Control - Xizi Health relies heavily on third-party manufacturers for its product lines, which raises concerns about quality control and product safety, as evidenced by consumer complaints [7][8].

Core Viewpoint - Hunan Xizi Health, led by entrepreneur Liu Jianwei, is preparing for an IPO on the Hong Kong Stock Exchange, aiming to capitalize on the growing market for sports nutrition products [1][2]. Company Overview - Hunan Xizi Health has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [2]. - The company operates in the sports nutrition sector, owning four proprietary brands: FoYes, fiboo, Guben Diary, and Hot Rule, offering products such as protein powders, functional gummies, and coffee [2]. Leadership and Background - Liu Jianwei, the chairman and founder, is a self-made entrepreneur who graduated from Hunan Engineering Vocational and Technical College with a degree in logistics management [3][4]. - He has spent over a decade building a successful nutrition brand, with annual revenue exceeding 10 billion yuan [4]. Brand Development - Initially focused on third-party brand operations, Liu identified opportunities in the nutrition market and pivoted to develop proprietary brands [5]. - The four brands cover various segments, including professional training, health maintenance, weight management, and daily nutrition needs [6]. Product Performance - The fiboo brand, launched in 2021, targets women's health and has seen significant sales, with its top-selling iron-rich gummies priced around 90 yuan and over 200,000 units sold [6]. - As of November 2025, fiboo ranked first in GMV for various vitamins and minerals on Douyin [7]. - FoYes, launched in 2024, focuses on high-quality protein products, while Hot Rule, introduced in April 2025, aims at Gen Z consumers with trendy flavors [8][9]. Financial Performance - The revenue share from proprietary brands increased from 42.4% in 2023 to 97.3% by September last year [10]. - For the first nine months of 2025, the company reported revenue of 1.609 billion yuan, surpassing the total revenue for 2024, with a net profit of 127 million yuan and a record high gross margin of 59.5% [10]. - The company's shareholders include institutions like Dacheng Caizhi and Zhongguang Tianze, with Liu holding a direct stake of 12.4% and an indirect stake of approximately 57% through Xizi Technology [10]. Sales Strategy - The company's sales strategy is heavily focused on online channels, with 99% of revenue generated from online sales, primarily through Douyin [10]. - If the IPO is successful, the funds raised will be used to expand sales channels and distribution networks, solidifying its position in the sports nutrition and functional food markets [10].

Core Viewpoint - The company has successfully transformed its business model from third-party brand agency to self-owned brand operation, significantly increasing its revenue and profitability through a strong focus on its proprietary brands [1][5][17]. Business Operations and Model - Xizi Health is a sports nutrition and functional food company with products including protein powder, creatine, and functional gummies, operating under four proprietary brands: FoYes, fiboo, Gu Ben Ri Ji, and Hot Rule [1]. - The revenue share from self-owned brands surged from 42.4% in 2023 to 97.3% in the first nine months of 2025, becoming the main revenue driver [1]. Revenue and Growth - The company reported a revenue of 1.692 billion yuan in 2024, a 17.0% increase from 1.447 billion yuan in 2023, with revenue for the first nine months of 2025 reaching 1.609 billion yuan, reflecting a 23.0% year-on-year growth [2][3]. - The core brand FoYes showed exceptional performance, generating 562 million yuan in the first nine months of 2025, a staggering increase of 364.2% year-on-year, accounting for 35.0% of total revenue [2]. Profitability Metrics - The gross margin improved from 44.4% in 2023 to 59.5% in the first nine months of 2025, driven by the higher margin of self-owned brands, which reached 60.3% compared to 30.8% for third-party brands [3][4]. - Net profit for 2024 was 149 million yuan, a significant increase of 59.0% from 94 million yuan in 2023, but only a slight increase of 1.9% to 118 million yuan in the first nine months of 2025 [3][4]. Revenue Structure Changes - Self-owned brand revenue in 2024 was 1.498 billion yuan, a 144.0% increase from 614 million yuan in 2023, and further increased to 1.567 billion yuan in the first nine months of 2025, a 38.7% year-on-year growth [5]. - In contrast, revenue from third-party brands plummeted by 76.5% to 194 million yuan in 2024 and further declined to 43 million yuan in the first nine months of 2025 [5]. Customer and Supplier Concentration - The concentration of customers decreased significantly, with the top five customers accounting for only 8.1% of revenue in the first nine months of 2025, down from 21.6% in 2023 [6]. - Supplier concentration remains high, with the top five suppliers accounting for 45.0% of purchases, indicating potential supply chain risks [6]. Management and Shareholding Structure - The company's shareholding is highly concentrated, with major shareholders controlling 77.85% of the equity, posing a risk of major shareholder influence [7]. - The core management team has an average industry experience of 15 years but lacks international market experience, which may hinder overseas expansion plans [7]. Research and Development Investment - R&D spending is notably low, with only 0.7% of revenue allocated to R&D in 2025, significantly below industry standards [9][10]. Financial Challenges - The company faces financial challenges, including high sales expenses, with a sales expense ratio of 47.0%, which is significantly above the industry average [15]. - Operating cash flow has been declining, dropping from 2.70 billion yuan in 2023 to 0.66 billion yuan in the first nine months of 2025, a decrease of 75.6% [11][12].